Research projects financed from EU funds

„Innovative, Polish - German cross-border program for early diagnosis and treatment of rare diseases in newborns – RareScreen”

 

Project no.

INT-10

Implementation period

01.05.2017. – 30.04.2020

Project value

3 395 562,31 EUR

Financial support for the IMC

223 827,10 EUR

Project partners

Universitätsmedizin Greifswald  – Lead Partner

Ernst-Moritz-Arndt-Universität Greifswald
Pomorski Uniwersytet Medyczny w Szczecinie (Pomeranian Medical University in Szczecin)
Samodzielny Publiczny Szpital Kliniczny nr 1 PUM w Szczecinie (Independent Public Clinical Hospital No.1 of the Pomeranian Medical University in Szczecin)
Uniwersytet Medyczny Charité w Berlinie (Charité – Universitätsmedizin Berlin)
Instytut Matki i Dziecka w Warszawie (Institute of Mother and Child in Warsaw)
Instytut Pomnik Centrum Zdrowia Dziecka w Warszawie (The Children’s Memorial Health Institute in Warsaw)

The project is a unique at European scale initiative concerning cross-border cooperation between Poland and Germany in the area of early diagnosis and treatment of genetically determined rare diseases in newborns. The project involves  widening the scope of diagnosed congenital metabolic defects and other rare diseases diagnosed on the basis of population screening of newborns from  West Pomerania, Mecklenburg-Western Pomerania and Brandenburg. For the newborns in Western Pomerania, the existing screening panel will be enlarged with galactosemia and a unique at European scale pilot study for severe combined immunodeficiency (SCID), familial hypercholesterolemia and selected congenital hemoglobinopathies as well as biotinidase deficiency.

Institute of Mother and Child provides IT infrastructure for the program. Participating in the project, IMC will enrich experience in newborns screening for diseases, which currently are not included in the obligatory screening panel. It concerns the diagnosis of SCID, biotinidase deficiency and familial hypercholesterolemia. In the EU, the screening for SCID has got the status of a pilot study and requires expanded population studies, validation, setting standards as well as analytic-diagnostic algorithm. It will be possible thanks to participation in the project of partners from various centres, An important benefit for the Institute will also be the possibility of developing new analytical methods including  molecular and enzyme activity research, participation in joint research, presentations at national and international scientific conferences. The research will provide the basis for possible implementation of new diseases into the screening of the entire population.

The project is financially supported from European Union funds under the European Regional Development Fund, Cooperation Program Interreg VA Mecklenburg-Vorpommern/Brandenburg – Poland.

‘Mazovia Centre for Diagnostics and Therapy of Musculo-Skeletal Cancer in Children and Adolescents'

Project no.

RPMA.01.01.00-028/10-00

Implementation period

2014–2015

Project value

PLN 3,889,579.60

Financial support

3,306,142.66

Project partners

Instytut – Pomnik Centrum Zdrowia Dziecka w Warszawie (Children's Memorial Health Institute in Warsaw)

Uniwersytecki Szpital Dziecięcy w Krakowie (University Children's Hospital in Kraków)

Samodzielny Publiczny Szpital Kliniczny nr 6 Śląskiego Uniwersytetu Medycznego w Katowicach - Górnośląskie Centrum Zdrowia Dziecka im. Jana Pawła II (Independent Public Clinical Hospital No. 6 at the Medical University of Silesia in Katowice – the Pope John Paul II Upper Silesian Health Centre for Children)

Śląski Uniwersytet Medyczny w Katowicach (Medical University of Silesia in Katowice)

Uniwersytet Medyczny w Białymstoku (Medical University of Bialystok)

Uniwersytecki Dziecięcy Szpital im. L.Zamenhofa w Białymstoku (L.Zamenhof University Children's Hospital in Bialystok)

COPERNICUS Podmiot Leczniczy Sp. z o.o.

Uniwersyteckie Centrum Kliniczne w Gdańsku (University Clinical Centre in Gdańsk)

Gdański Uniwersytet Medyczny (Medical University of Gdańsk)

Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu (Wrocław Medical University)

Samodzielny Publiczny Szpital Kliniczny nr 1 we Wrocławiu (Independent Public Clinical Hospital No. 1 in Wrocław)

The project is designed to establish a modern diagnostic laboratory with the capacity to conduct genetic examinations, to expand the IMC network infrastructure and create an IT platform based on the above elements. This will allow the partners to collect data on diagnosis, treatment and scientific research in the field of paediatric oncology throughout Poland and, thus, will significantly reduce the number of deaths among children being treated for cancer and tumours.

It is planned that the final output of the project will consist in a fully operational ICT system, which will reduce the time needed to prepare diagnosis and the waiting time for a consultation in oncology, radiology and pathomorphology. The patient classification for surgical procedures will be streamlined. The collected data will be used to develop alternative therapies and will contribute to the academic progress among oncologists. By enabling the continuation of advanced research in multidisciplinary teams conducting research in the field of diagnosis and treatment of children with cancer, the project will be help to satisfy the most important socio-economic needs of Poland and will help to make a better use of the R&D capabilities, also enhancing the competitiveness of the region.

The project provides for the preparation of facilities for a central histopathological laboratory, with the capability to conduct unique genetic research. It will serve as a hub for a nationwide network of laboratories connected with a specialist application for online consultations and multi-centre consultations. In this way, new standards will be created and modelled during the project. Moreover, scanners will be used in the process of creation of the IT platform to collect data on diagnosis, treatment and research in the field of paediatric oncology in Poland. This will help to establish a multi-centre platform for scientific co-operation.

The project is co-financed by the European Union from the European Regional Development Fund, under the Regional Operational Programme of the Mazowieckie Voivodship, 2007–2013.

Information about the Regional Operational Programme of the Mazowieckie Voivodship 2007–2013 can be found online at:

www.mazowia.eu

01-pomeraniahttp://www.interreg4a.info/fileadmin/user_upload/bilder/logos/Int4a_Slogan.png

‘Pomerania' is a model region in territorial co-operation for newborn screening

Project No.

INT-10-0008

Implementation period

2011–2014

Project value

EUR 2,449,975.00

Financial support for the IMC

EUR 237,700.00

Project partners

Universitätsmedizin Greifswald – Lead Partner

Ernst-Moritz-Arndt-Universität Greifswald

Pomorska Akademia Medyczna w Szczecinie
(Pomeranian Medical Academy in Szczecin)

Institute of Mother and Child in Warsaw

The main goal of the project is to create a model system for the screening of newborns in the Pomerania Euroregion. This system is intended to be unique in Europe as a model of international co-operation in the field of neonatal screening. Its implementation will expand the range of congenital metabolic diseases and endocrine disorders included in the screening of all newborns in the Pomerania Euroregion (up to 14). As the second Polish partner, the IMC participates in the project in order to implement the expanded newborn screening tests in the Polish system covering the entire country. Under the project, the IMC has the following responsibilities:

    1. Developing and implementing an IT system to ensure a database maintenance and information flow between the partners (in particular, research results),
    2. Performing molecular tests for the screening of cystic fibrosis (CF) and congenital adrenal hyperplasia (CAH),
    3. Conducting comparative analysis and epidemiological screening tests, statistical analysis, optimisation of screening methods for rare metabolic defects, cystic fibrosis and congenital adrenal hyperplasia,
    4. Participating in the creation of a cross-border centre to expand the panel for neonatal screening.

The project is financially supported from European Union funds under the European Regional Development Fund, ‘European Territorial Co-operation' Operational Programme – ‘Trans-border territorial co-operation' Mecklenburg-Vorpommern / Brandenburg –Zachodniopomorskie Voivodship 2007–2013.